A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of AZD9898 in Healthy Volunteers and Asthma Patients.
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
Price : $35 *
At a glance
- Drugs AZD-9898 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 15 Jan 2018 Status changed from recruiting to discontinued.
- 20 Jun 2017 Planned End Date changed from 12 Dec 2017 to 18 Dec 2017.